Skip to content

Study · Other design · 2020

2 results

Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis.

Tajik N, Frech M, Schulz O, Schälter F, Lucas S, Azizov V, Azizov V, Dürholz K, Steffen F, Omata Y, Rings A, Bertog M and 19 more

Show all authors

Rizzo A, Iljazovic A, Basic M, Kleyer A, Culemann S, Krönke G, Luo Y, Überla K, Gaipl US, Frey B, Strowig T, Sarter K, Bischoff SC, Wirtz S, Cañete JD, Cañete JD, Ciccia F, Schett G, Zaiss MM

Nature communications24 Apr 2020Cited by 401 (Europe PMC)

PMID32332732 (opens in a new tab)PMCIDPMC7181728 (opens in a new tab)DOI10.1038/s41467-020-15831-7 (opens in a new tab)PepBankPUB-32332732
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Gut microbial dysbiosis is associated with the development of autoimmune disease, but the mechanisms by which microbial dysbiosis affects the transition from asymptomatic autoimmunity to inflammatory disease are incompletely characterized. Here, we identify intestinal barrier integrity as an important checkpoint in translating autoimmunity to inflammation. Zonulin family peptide (zonulin), a potent regulator for intestinal tight junctions, is highly expressed in autoimmune mice and humans and can be used to predict transition from autoimmunity to inflammatory arthritis. Increased serum zonulin levels are accompanied by a leaky intestinal barrier, dysbiosis and inflammation. Restoration of the intestinal barrier in the pre-phase of arthritis using butyrate or a cannabinoid type 1 receptor agonist inhibits the development of arthritis. Moreover, treatment with the zonulin antagonist larazotide acetate, which specifically increases intestinal barrier integrity, effectively reduces arthritis onset. These data identify a preventive approach for the onset of autoimmune disease by specifically targeting impaired intestinal barrier function.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalOther designEfficacy outcome

    In autoimmune models, larazotide acetate reduced arthritis onset.

    In plain wordsIn autoimmune models, larazotide acetate reduced arthritis onset.

    Peptide
    Larazotide
    Outcome
    DecreaseArthritis onset
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, treatment with the zonulin antagonist larazotide acetate, which specifically increases intestinal barrier integrity, effectively reduces arthritis onset.
  2. 02AnimalOther designMechanism

    In autoimmune models, larazotide acetate increased intestinal barrier integrity.

    In plain wordsIn autoimmune models, larazotide acetate increased intestinal barrier integrity.

    Peptide
    Larazotide
    Outcome
    IncreaseIntestinal barrier integrity
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, treatment with the zonulin antagonist larazotide acetate, which specifically increases intestinal barrier integrity, effectively reduces arthritis onset.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.